Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Dow
US Department of Justice
Chubb
Cerilliant
QuintilesIMS
Healthtrust
Deloitte
Medtronic
Daiichi Sankyo

Generated: August 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076139

« Back to Dashboard
NDA 076139 describes FOSINOPRIL SODIUM, which is a drug marketed by Apotex Inc, Actavis Labs Fl Inc, Invagen Pharms, Watson Labs, Teva, Aurobindo Pharma Ltd, Prinston Inc, Ranbaxy Labs Ltd, Upsher-smith Labs, Mylan, Emcure Pharms India, Sun Pharm Inds Ltd, Aurobindo Pharma, and Sandoz, and is included in twenty NDAs. It is available from sixteen suppliers. Additional details are available on the FOSINOPRIL SODIUM profile page.

The generic ingredient in FOSINOPRIL SODIUM is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.

Summary for NDA: 076139

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 076139

Suppliers and Packaging for NDA: 076139

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FOSINOPRIL SODIUM
fosinopril sodium
TABLET;ORAL 076139 ANDA Teva Pharmaceuticals USA, Inc. 0093-7222 0093-7222-10 1000 TABLET in 1 BOTTLE (0093-7222-10)
FOSINOPRIL SODIUM
fosinopril sodium
TABLET;ORAL 076139 ANDA Teva Pharmaceuticals USA, Inc. 0093-7222 0093-7222-98 90 TABLET in 1 BOTTLE (0093-7222-98)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Nov 25, 2003TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Nov 25, 2003TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Nov 25, 2003TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Queensland Health
Colorcon
Harvard Business School
Covington
US Department of Justice
Cantor Fitzgerald
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot